Recent

% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

dscobash 147 posts  |  Last Activity: 16 hours ago Member since: Mar 21, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • dscobash dscobash 16 hours ago Flag

    What is your impression of a company who were indicating talks with the FDA were going extremely well just prior to receiving a CRL sending them all the way back to the need of redoing a Phase III trial??? The only way for that CRL to have been worse is if it would have had criminal charges attached. I think you are missing the point completely. AEZS is an exceptionally incompetent biotech company who are extremely deceptive about their prospects in order to excessively dilute shareholder value as their executives are paid amounts of money as though they are already successful. They’re not. Not even close. If you failed and lost money for the company you work at for 14 straight years would you be receiving a cash bonus and praise for your accomplishments this year??? You want to pretend that this company has just as good a chance of succeeding as the next biotech and that is where you yourself fail. Those who wish to ignore this company’s entire history are just setting themselves up for more of the same. That’s fine. Believe whatever you like. Just don’t try and convince others to believe in your own ignorance. When people try and do that here on this board I often step in to present a heavy dose of reality.

    AZ-108 had a 40 handpicked patient Phase II trial that showed less robust results than the Perfosine Phase II trial
    NO partners were interested in pursuing AZ-108 and AEZS had to go it alone relying on the dilution of shareholder value. The float has since more than tripled and the trial isn’t even half way completed. The company has in the meantime positioned itself to be out of compliance with the NASDAQ (an index which is currently at its all-time high). The company indicated that the Phase III trial would only cost $30 million to complete and that Ergomed would absorb a third of those costs. So that makes $20 million to the company and yet since announcing that they have burned through more than $60 million dollars and have still not arrived at the interim analysis. So technically they should have only spent $10 on the trial to date. So what did they spend the other $50 million on??? They sold the rights to AZ-108 for Asia’s largest market for $1 million dollars??? Less than 2 weeks’ worth of company cash burn. Does that sound like AZ-108 is doing well in its Phase III open label trial? There are so many obvious clues that the trial is going poorly it’s hard to imagine the ridiculous optimism expressed here. We are talking about a company with a 14 year proven track record of complete failure who just did their largest offering in their entire history for 62 cents a share.

    There is nothing to indicate that the trial is going well and plenty to indicate just the opposite. You can’t predict outcomes of drug trials by the lengths of time lines. Perifosine went months past projected “events” and was a complete failure. TWICE!!! If there was anything to Dox’s algorithm do you honestly believe the stock would be trading pennies from its all-time low? The trial is open label and the stock is languishing near its lows and the company just doubled the float AGAIN near those lows. This is a despicable company run by despicable people. Listen to everything Dodd has said since he first arrived and compare it to what he did. Then listen to Dodd praise his accomplishments in meeting all of his goals. Then look at the share price performance and draw some reasonable conclusions and apply them to future outcomes. I’m not against speculating in biotech investing but investing in AEZS could hardly be considered “speculating”. It’s more like donating your money to the Dudd and Turdpin fund for their own inbetterment. They have been making a killing since they both started working at AEZS. To what benefit to shareholders?

    Same as it ever was

  • dscobash dscobash Apr 24, 2015 8:57 PM Flag

    There are plenty of “facts” known about this company.

    The company’s 100% failure rate for partners and investors over a 14 year period is a “fact”
    Dodd’s performance as CEO of this company losing shareholders over 70% during the last 2 years is a known “fact”
    The company’s inability to find any willing CREDIBLE partners is a “fact”
    The company’s excessive burn rate beyond their projected trial costs is a “fact”
    The company’s excessive dilutive practices are a “fact”
    The company’s continued setting of new all-time low share prices is a “fact”
    The company’s pumpers on this board being wrong for 14 years is a “fact”
    The company’s “bashers” on this board being right for 14 years is a “fact”
    Every single one of your predictions on this board being wrong is a “fact”

    And I could go on for hours with “facts” but what’s the point when the share price is, and has been, the ultimate “fact”. Maybe if pumpers like yourself ever developed a shred of credibility some “facts” could be argued against. But since you have proven yourself so many times in the past to be the same old flavor of pumper that has always existed here, “facts” have no real meaning.

    Same as it ever was

  • dscobash dscobash Apr 24, 2015 8:06 PM Flag

    The explanation is that the people who run this dilutive operation wish for it to continue for as long as possible while they make millions producing nothing but lost value for their investors. Just like they always have. Their other Phase III failures were drug out to their final devastating conclusions the same way. The Perfosine Phase III trial lasted longer than anticipated while everyone speculated that Peri was extending patients’ lives. That’s not what was happening. The control arm group receiving the placebo was living longer than the trial design expected. Perifosine was actually shortening the lives of the people receiving it even though the trial lasted far longer than the Company said it would.

    Of course they were diluting like mad men the entire time much the same way that they currently are. And that is the most obvious indicator. Why would AEZS be diluting to the degree they are at the prices they are if everything was going well? They had enough cash to arrive at the interim analysis timeline they have been giving for over a year. If AZ-108 was significantly extending patients’ lives in this open label trial, why not wait to do their biggest, most dilutive, offering in their entire history at something more than 10 cents above their all-time closing low? Better yet, why not wait until they had a deep pocketed partner to complete the trial of something that was showing so much promise?

    Let’s be honest, even if it’s not in the nature of this boards pumpers to do so, and admit that the recent offering, which doubled the float at 62 cents, and added warrants tripling the float at 81 cents, while having already received a listing warning from the NASDAQ, was a desperate move from a desperate company. Not a confident move from a company doing well in its Phase III trial of its next great failure. Look at any chart of any period in time for this dilution machine and explain again how well things are going. Dodd has been doing just that since he first arrived and the stock is 75% lower since his opening optimistic speech two years ago. Believing AEZS is doing well and one share of the company stock wouldn’t buy you a cup of coffee in a small Columbian mountain side village.

    Your logic is as flawed as it always has been. Did you vote “yes” to the reverse split? Or are employees of the toxic underwriters of this dilution trap forbidden to own shares of the 56 cent a share mess they are pumping for Turpin on this message board? From over $70 a share to 56 cents a share with a 100% failure rate over 14 years and everything is now different because you say so? The share price disagrees whole heartedly. And shareholders are being played until the company can execute its next devastating reverse split so they continue dilution of shareholder value while Dodd decides on the size and layout of his next yacht.

    Same as it ever was

  • Reply to

    As the Sewer Stinks -

    by dhudson100 Apr 23, 2015 10:22 AM
    dscobash dscobash Apr 24, 2015 10:24 AM Flag

    And we are all certain that after you are proven wrong “AGAIN” that you will continue unashamedly posting your dribbling nonsense. Such is the life of an AEZS pumptart. Over 14 straight years of being completely, undeniably, categorically, “WRONG”. How could a single group of narrow-minded people be so wrong for so long and continue to bathe in total ignorance? You represent the positive sentiment of this dilution disaster extremely well. You also clearly demonstrate that Turpin is too cheap to hire pumpers with a fraction of a brain or a shred of dignity. I guess he feels it’s just that much more money in his pocket.

    Same as it ever was

  • Reply to

    I've sold my positions. I am out.

    by wowowscott Apr 23, 2015 10:32 AM
    dscobash dscobash Apr 23, 2015 11:01 AM Flag

    You don't want to continue averaging down for the next few years? Turpin will have plenty of "cheaper" shares to sell for a while longer. And Dodd and Turpin would really like your continued support while they continue to get richer.

    Same as it ever was

  • Reply to

    A legal question about the reverse/split??????

    by rendnilk Apr 22, 2015 6:58 PM
    dscobash dscobash Apr 22, 2015 8:19 PM Flag

    Take them to court on what grounds? Their argument is that a reverse split is in the best interests of their shareholders. Just like the last time up over $3 a share. They have too many “forward looking statements” to be liable in any way for their poor performance for their shareholders. You can’t sue them because they are obliterating shareholder value with endless dilution and poor management. Even though Dodd and Turpin have already made millions.

    No one on this board really cares what I have had to say over the last 3 years but no one has been anywhere near as accurate as my presented detailed opinions. While biotech investing is very speculative there are very few companies out there as bad as this one. It’s run by deceptive greedy old men who always profit at the great expense to their decimated investors. Always has been and always will be. Their pipeline is full of failures waiting for them to capitalize on after failing. AZ-108 will only be their next great failure. To date this company has a 14 year 100% failure rate. Dodd has been CEO for 2 years and the stock is down over 70% and the float has more than tripled. And yet he boasts about meeting all of his goals. He never mentions one of his goals being erosion of shareholder value even though it being his greatest accomplishment.

    There is a very real reason that they have no credible partners and that the share price sits pennies from its all-time low. As much as I’m sure you would like too, you can’t sue them for being incompetent old greedy men without a clue. You should have done better DD and listened to posters on this board who have been warning investors for years rather than the bogus pump monkeys who are flipping for pennies as they lie through their yellow stained teeth. Speaking of which, jimboob has been a pumper here since multiples of the current price while labeling others as being “idiots”. It’s just how he likes to fly.

    Same as it ever was

  • Reply to

    Shaked out the day-traders, see why???

    by qianz31 Apr 16, 2015 7:16 PM
    dscobash dscobash Apr 16, 2015 9:01 PM Flag

    “Good post”???

    How? Why? The post makes no sense. Who is being shaken out? Sounds like a bunch of penny pumping traders are flipping for pennies and a 33% tax liability. The header title is “Shaked out the day-traders, see why???” Then the post goes on to describe what I have been pointing out since day one. This stock is filled with penny pump and dump scam artists. They come here making statements like “this stock will soon be a dollar” …….. “Phase III data out this month” ……. “buy out soon by Chinese” ……… “Will be $5 soon” …………… “10 bagger this year” while the whole time they are all actually selling for a nickel profit. It’s been going on here for years. The highs are always lower. And the lows are always lower. And the pumpers are always trying to deceive someone else into buying their trading scalp. That is the environment that Dodd has nurtured. That is the reality that Turpin has created. And that is the nonsense that you buy into and want everyone else to believe.

    There will soon be another reverse split. And it will be very bad for shareholder value. And nothing will change that now. The company would not have done the last offering at 62 cents and included 75 million shares worth of warrants at 81 cents a share if the Phase III trial for AZ-108 were going well. Just like they wouldn’t have dropped 10 million shares through the ATM leading up to the PDUFA date for AZ1-30 if talks were going well with the FDA as Dodd always indicated they were. All deceptions, all the time with this company, always ending in bad news for shareholders. But executives always still get a cash bonus on top of their already obscene salaries. AZ-108 doesn’t have a snowballs chance and yet pumpers act like it’s only a matter of time before its great success. Well Dodd and Turpin aren’t waiting for that to happen. They always take their cash now while the stock is at all-time new lows. And they know better than any pumper on this board what happens next. And knowing what they know they always want their money now. Why do you think that is?

    Same as it ever was

  • dscobash dscobash Apr 16, 2015 6:38 PM Flag

    The company said the Phase III trial for AZ-108 would only cost $30 million dollars. After Ergomed’s supposed $10 contribution the trial should have only cost $20 million. And yet after 2 years and $60 million dollars of cash burn they haven’t even reached the midterm analysis? Think maybe Mr. Dodd doesn’t know what he’s talking about? Or is he just that deceptive?

    Same as it ever was

  • Reply to

    watch the last hour of trading, good bye shorts

    by dolphinreo Apr 16, 2015 2:55 PM
    dscobash dscobash Apr 16, 2015 6:34 PM Flag

    “never return”?

    Like you promised to do earlier today if the stock didn’t reach a dollar a share in an hour? Another deceptive lying penny pump and dumper on the AEZS message board? Gee, what are the chances? Like 100%? Probably higher than that.

    This stock is a pump and dump simple minded game for the world’s most unintelligent pumpers. Pumpers who can’t comprehend that the vast majority of investors in this world are much smarter than they are. Check out a 10 year chart to see just how intelligent pumpers have been. Too funny. Dodd and Turpin count on your low IQ and your enthusiasm for their mediocrity. They will show just how appreciative they are after the next reverse split. Make sure to vote “yes” as the company recommends.

    Same as it ever was

  • Reply to

    True longs, i have question.

    by duanucan Apr 14, 2015 9:32 PM
    dscobash dscobash Apr 14, 2015 11:33 PM Flag

    And without “great test results”?

    The stock is down more than 70% since Dodd became CEO. He didn’t start his position in this company warning of the difficult times ahead. He started by making it clear that “shareholder value” was his priority and that the future was amazingly bright and that the company was greatly undervalued with great untapped potential. He also said he would get the NDA filed within one quarter’s time. Two years later after a CRL and a number of Phase II trial disappeared and over 100,000,000 shares of dilution (No I’m not making that up) and a 70% lower share price and all you still see is the potential? You and I argued about the quality of this investment close to $2 a share more than two years ago. All you saw back then was the potential ahead. How’d that work out for you? All I see is the coming reverse split and continued dilution for years on the way to continued failure. Just like I did 2 years ago.

    Same as it ever was

  • Reply to

    FDA reversal awesome

    by fishmercedriver Apr 14, 2015 2:39 PM
    dscobash dscobash Apr 14, 2015 9:02 PM Flag

    Receiving a CRL that ends up requiring a whole new Phase III confirmatory trial is a “reversal” on the part of the FDA in your mind? What is the average intelligence level of your typical AEZS pumper? I think your post answers that quite well. Too funny

    Same as it ever was

  • dscobash dscobash Apr 14, 2015 10:13 AM Flag

    Happy to present an honest opinion based on reality even though it obviously troubles you. But then deceptive pumping fools never did like an honest assessment of this company. Go figure

    Same as it ever was

  • dscobash dscobash Apr 14, 2015 10:09 AM Flag

    It’s not how much a company raises dily, it’s how much they spend and the value that is produced. You keep talking about longshot success like it’s already a given. Like the NDA for AZ-130 was a given? Or the Phase III trial for Perfosine for MM was a given? Or the Phase III for Perfosine of BC was a given? Or the Phase III for Cetrorelix was a given? Or any of the many Phase II trials now canceled or put on hold were all a given? Over $300 million raised and spent to date and what value has been produced for shareholders? But since you now hold shares in this dilution trap everything has now changed? The company is going to turn over a new leaf and actually start to create value for their shareholders? Is that why they just sold 60 million units consisting of shares and warrants for 62 cents a share? Less than half the price of the last offering. While the stock was trading North of 80 cents a share?

    Don’t worry dily the reverse split will fix everything for Dodd and Turpin. Make sure you vote “yes” to the company’s recommendation for an up to 1 for10 reverse split. Should do wonders for shareholder value while you wait for those “billions”

    Same as it ever was

  • dscobash dscobash Apr 14, 2015 9:52 AM Flag

    Guess that’s why they just helped underwrite 60 million shares at less than half their target price which also included warrants for an additional 75 million shares if fully diluted. Can AEZS ever be “fully diluted”. Turpin is sure trying his best. The reverse split will fix everything. Except for shareholder value.

    Same as it ever was

  • dscobash dscobash Apr 13, 2015 10:13 PM Flag

    Sorry best, not to rain on your parade but this is not even close to being an “insurance policy”. It is just another company expense. Another cash drain acting as a dangling carrot to lure investors into their quicksand pit of dilution. Even if successful AZ-130 was never expected to bring much in. Even Dodd started tempering revenue expectations after making his now infamous claim of it being a “$200 million dollar market opportunity”. Was AZ-130 a “$200 million dollar market opportunity”? Or was it this company’s next great bumbling failure? Most analysts agreed that AZ-130 was good for $20 million in annual revenues at best. Which would be hardly enough to offset expenses associated with production and marketing. AZ-130 was used as a dangling carrot in front of investors for more than 5 years before ending in this company’s latest in a long line of disasters for which management always received high praise and bonuses. Next time will be no different.

    Over 18 months of clinical trials “AFTER” regulatory approval? Sounds like a long time and a lot of money to me for a company that is completely funded by dilution of shareholder value. They did the same thing with Perfosine. Like I’ve said many times before in the “past”. You don’t bet on something simply because it lost every single time for 14 straight years. You stop, take notice, and question something that has lost every single time for 14 straight years while executives were paid countless millions while congratulating themselves for a job well done. Not trying to make you feel bad about your own obvious convictions, but I am here to call a spade a spade. This company’s past speaks volumes about its abilities or desire to change its future.

    Same as it ever was

  • dscobash dscobash Apr 13, 2015 9:51 PM Flag

    Jason Kolbert has proven himself to be an even bigger buffoon that David Dudd if that can be believed. Time and time again. His “recommendations” are the butt of wall street jokes. He “reiterated” his $5 price target for this stock several times last year before upping his target to $6 a share the night before they announced a CRL from the FDA. How did Jason’s reiterated” price targets work out for shareholders back then? In my opinion he is either a complete smacked@ss moron or he is on the company payroll in some way. Maxim was one of the underwriters of the last offering. Jason Kolbert’s price targets are the kiss of death for anyone holding stock in that company. Check his past record and then try and figure out how he makes a living off of always being wrong. Just like Dodd.

    Same as it ever was

  • dscobash dscobash Apr 13, 2015 10:50 AM Flag

    It’s called a pump and dump “Dude”
    “see” this company’s entire history

    Same as it ever was

  • Man Dodd continues to knock’em out of the park. This is exactly the outcome I predicted and as I predicted it is the worst possible outcome. They are back to another Phase III trial for AZ-130 which Dodd indicates will “only” take another year and a half? Oh, and “pending regulatory approvals“, which this company has a history of totally botching up. When has Dodd ever met his own projected timeline? So let’s figure that for once he is right about something and the trial only takes 18 months to complete. When will they start? This company who can’t even file an proper NDA after 4 plus years of effort for a drug that already successfully completed a Phase III study is now going to be doing two Phase III clinical trials by themselves? What happened to Dodd’s moving away from being a development stage company into becoming a revenue generating commercial entity? How does anything Dodd says make sense?

    Oh, and Dodd also says that this should only cost another $6 million dollars. Sure, just like the Phase III clinical trial for AZ-108 was only supposed to cost $30 million dollars. Actually only $20 million after Ergomed’s contribution. And now $60 million dollars of shareholder value later after endless dilutive financings and uncountable failures and disappointments and still no mid-term analysis? Another Phase III confirmatory clinical trial will cost far in excess of what Dodd is indicating. The company will burn at least $60 million or more dollars before its completion. And there is no guarantee of success. This company’s track record almost gaurntees failure. And if successful then they have to start the NDA process all over again, which took more than 4 years to submit last time. All just to arrive at the point they already were more than a year ago. This is total pump and dump news designed to disguise the fact that the company will soon be doing another devastating reverse split. Why would anyone in their right mind buy this news? This is selling news for the recent purchasers of the last devastating offering.

    Hard to believe that Dodd is actually this bad of a CEO even for myself. From my perspective he is obviously a washed up old executive grabbing for all he can while doing nothing for anyone but himself. A monkey in a pink ballerina costume could easily have done the same job as Dodd over the last two years. Not only would the monkey have been much cheaper for shareholders, it would have been far more entertaining for them. As Chairman of the Board and as CEO Dodd gets to do whatever he likes. And so far what he seems to like to do is dilute his investors for whatever he can get away with.

    As is typical with this company, this was the worst possible outcome from an NDA that should have easily been successful from the start. The FDA sent them back to the completion of the Phase II level because of a poorly submitted NDA and Dodd is acting like everyone deserves a pat on the back? This company is easily the most incompetent bio-sham out there. Congratulations Mr. Dodd. Time to set up the next round of cash bonuses for what you feel was another job well done.

    Same as it ever was

  • Reply to

    Is this the new all time low close?

    by sargeantfury Apr 10, 2015 6:14 PM
    dscobash dscobash Apr 11, 2015 9:12 PM Flag

    I have no problem with the shareholders of this company. Just the opposite. I feel that they have been greatly taken advantage and abused by some of this industries worst executives. My personal opinion is that Turpin is a fraudulent criminal posing as a CFO where he oversees back room financing deals that are designed to take money away from investors and place it squarely in the hands of undeserving executives of this train wreck and their toxic underwriting analysts. Dodd has been talking the talk since he first arrived while he has been fumbling, bumbling, and diluting the entire time. This company knows better than anyone how this open label trial is going and they just did their largest offering in their long sordid history for half the price their last offering which underscores that things are just not going all that well.

    I wish all shareholders of this dilution trap the best of luck but that is all that’s left for them. Luck. Dodd is a buffoon with a bad haircut and Turpin is nothing more than a shareholder hitman. They are, and have been, spinning the truth to extract money from day one. The NDA for AZ-130 should have been a slam dunk for anyone with a thimble full of talent making a minor effort. Apparently Dodd played golf through the whole review process. All of that said, what “approved” drug are you under the impression that AZ-108 is based on? It’s not based on any drug I am aware of. It is only being used in combination with Doxorubicin in the current clinical trial to help offset the toxicity of that drug. You have to understand that the Phase II for Az-108 included about 40 handpicked patients and the outcome was not as robust as Perfosine’s Phase II trial. There is a very good reason that this company is now down to dilution of shareholders to fund everything, including their own outrageous salaries. They’ve hurt every partner or investor that ever gave them a chance. Their research and their science is obviously flawed and very questionable. They are the three card monty of the industry. And most investors are of aware of that now.

    Same as it ever was

  • Reply to

    Is this the new all time low close?

    by sargeantfury Apr 10, 2015 6:14 PM
    dscobash dscobash Apr 11, 2015 3:27 PM Flag

    Sorry but this an open label trial that is close to an interim review and there continues to be ZERO interest from ANYONE! The fact that AEZS had to go it alone is telling enough. But after all this time it has become very obvious that AZ-108 is not impressing ANYBODY. Least of all myself. Dodd has been using his time to prepare shareholders for the impending failure by pretending his focus has shifted towards being a commercial product selling company rather than a research based biopharmaceutical. In other words their pipeline is full of feces and he knows it. The Ascend arrangement is beyond ridiculous. Dodd is turning AEZS into a telemarking firm who specializes in selling other people’s products. Makes sense from the standpoint that AEZS has nothing to sell, and my feeling is Dodd believes that they never will. The problem is that there is no money in selling other people’s success stories in the bio world. At least not enough to maintain the extravagate spending and compensation of this company. Dodd is too embarrassed to spell out the commission structure. He will soon have to report to the world just how bad of a deal it is. Wait and see how minuscule the commissions are compared to how expensive it is to maintain a 20 person sales force.

    There is no question in my mind that AZ-108 is going to be a complete failure. They will likely squeak past interim analysis simply because the clinical trial has not detected a death directly attributable to AZ-108, but that will only serve to pump up the share price while Turpin continues his dumping of endless dilution for cash that never develops a pennies worth of value. The company has spent in excess of $300 million dollars to arrive at 52 cents a share, an undeniable pattern of incompetence and failure, and callus greedy executives who pay themselves as though they’ve actually succeeded at something. This company is the joke of the industry. The only aspect more ridiculous is Jason Kolbert. Who does he really think he’s kidding?

    Same as it ever was

AEZS
0.566-0.0090(-1.57%)Apr 24 4:00 PMEDT